We would like to thank Styles et al. for their response to our comment ‘Consulting the consultants: Avastin in the treatment of wet AMD’ [1]. The authors’ letter raises a number of interesting points, while highlighting the importance of patient understanding and misinformation in the Avastin issue.

The results of the survey of Fife wet AMD patients [2] were of great relevance to our own research in this area, particularly as we had undertaken a similar patient survey canvasing the views of Abergele wet AMD patients and found almost the opposite response. Our study, ‘Consulting the patients: Avastin in the treatment of Wet AMD (Part II)’ [3], showed that 18% of Abergele patients, if offered, would be likely to choose Avastin compared to 77% of Fife patients. 84% of Abergele patients felt an information leaflet would be useful, whereas only 11% of Fife patients wanted more information provided. It is certainly noteworthy to compare how varying patient views are within the different geographical cohorts of Northern Wales and East Scotland.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD